Appaloosa’s David Tepper reveals new position in Intel, raises bets on UnitedHealth

Appaloosa Management's Q2 filings reveal significant portfolio shifts, including a new $179.2 million stake in Intel amidst reports of potential U.S. government investment to boost domestic chip manufacturing, which saw Intel shares rise over 7%. The fund also dramatically increased its UnitedHealth Group allocation by 1,300% to $764.3 million, making it the second-largest holding, alongside continued accumulation in AI-related names like Nvidia, Taiwan Semiconductor, and Micron Technology. Conversely, Appaloosa cut exposure to Meta Platforms and Alphabet by over 25% each, indicating a strategic reallocation away from some Magnificent Seven stocks.

Analysis

Appaloosa Management's Q2 regulatory filings reveal a series of high-conviction thematic bets, shifting capital decisively within the technology and healthcare sectors. The fund initiated a new $179.2 million position in Intel (INTC), a move that aligns with reports of potential U.S. government investment to bolster domestic chip manufacturing. This catalyst contributed to a 7% single-day stock increase and supports Intel's 19% rally in 2025, marking a reversal from its poor performance in 2024. Concurrently, the firm made a significant contrarian bet on UnitedHealth Group (UNH), increasing its stake by 1,300% to $764.3 million, making the beaten-down insurer its second-largest holding; this move is notably echoed by Berkshire Hathaway, which also disclosed a new stake. Further concentration is evident in the artificial intelligence space, where Appaloosa aggressively increased its exposure to semiconductor infrastructure players, raising its Nvidia (NVDA) holding by 483% to $276.5 million, its Taiwan Semiconductor (TSM) stake by over 279%, and doubling its position in Micron Technology (MU). This accumulation in AI hardware was funded in part by a strategic rotation away from other Magnificent Seven names, as the fund trimmed its holdings in Meta Platforms (META) and Alphabet (GOOGL) by more than 25% each.

Key Decisions for Investors

• Investors should re-evaluate Intel's turnaround potential, as Appaloosa's new stake, backed by the prospect of U.S. government investment and easing political headwinds, signals a significant de-risking of the domestic chipmaker's outlook.
• The substantial increase in the UnitedHealth position by both Appaloosa and Berkshire Hathaway suggests a strong institutional conviction in a value opportunity, warranting a closer look at the insurer for those seeking contrarian plays in the healthcare sector.
• Appaloosa's portfolio actions indicate a clear preference for AI hardware and infrastructure (NVDA, TSM, MU) over large-cap ad-tech platforms (META, GOOGL), suggesting investors may consider tilting their own tech exposure towards the foundational semiconductor layer of the AI buildout.
• Monitor developments related to government support for the U.S. semiconductor industry, as confirmation of a federal stake in Intel could serve as a major catalyst for the stock and its domestic peers.